Inspection Record

Maitland Labs of Central Florida — FDA 483 Findings

US FDAInspected 2019-06-17Published 2020-03-09 8 findingsStability and storageAseptic processing and sterility assuranceLaboratory and QC controlsLabeling and packagingEquipment and facility

Inspectors Jessica L PressleyThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

2Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

3Aseptic processing and sterility assurance

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring enviromnental conditions.

5Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

6Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

7Labeling and packaging

The labels of your outsourcing facility's drug products are deficient.

8Equipment and facility

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

About this record

Extracted automatically from the document US FDA published on 2020-03-09. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Maitland Labs of Central Florida company profile — full history US FDA documents, 2020 Go to Findings search